• Users Online: 554
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2019  |  Volume : 2  |  Issue : 1  |  Page : 8-15

Role of sclerostin, fibroblast growth factor-23, and Klotho in hemodialysis patients


1 Department of Clinical Pathology, National Institute of Urology and Nephrology, Cairo, Egypt
2 Department of Nephrology, National Institute of Urology and Nephrology, Cairo, Egypt

Correspondence Address:
Azza A I. Elmenyawi
Department of Clinical Pathology, National Institute of Urology and Nephrology, Cairo
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/JMISR.JMISR_84_18

Rights and Permissions

Introduction Chronic kidney disease–mineral bone disorder leads to decreasing bone health. Sclerostin is produced by osteocytes similar to fibroblast growth factor-23 (FGF-23) and might upregulate the FGF-23 production by the osteocyte. FGF-23 may act as a mineralization inhibitor. Klotho serves as an obligate coreceptor for the FGF-23 and represents a marker of chronic kidney disease–mineral bone disorder. Aim We examined the association between serum sclerostin, FGF-23, Klotho, parathyroid hormone, high-sensitivity C-reactive protein (hsCRP), and phosphorus levels in hemodialysis (HD) patients. Patients and methods A total of 63 HD patients in the National Institute of Urology and Nephrology and 20 controls were enrolled in the study. Serum sclerostin, FGF-23, Klotho, parathyroid hormone, hsCRP, and phosphorus levels were assayed. Results We found that serum sclerostin, FGF-23, Klotho, and hsCRP levels of the HD patients were higher than controls [median and interquartile range are 1.379 (0.217–11.680) ng/ml, 61.71 (9.821–565.5) pg/ml, 201.74 (90.53–402.73) pg/ml, and 25.79 (12.10–41.92) mg/l vs. 0.535 (0.169–0.830) ng/ml, 33.077 (10.45–67.342) pg/ml, 349.49 (201.23–721.5) pg/ml, and 4.375 (2.27–6.21), respectively; P < 0.001). The sclerostin level was significantly correlated with the serum phosphorus, FGF-23, Klotho, and hsCRP (r = 0.296, P < 0.007; r = 0.239, P = 0.03; r=−0.336, P = 0.002; and r = 0.469, P < 0.001, r espectively). Moreover, FGF-23 was significantly correlated with the serum phosphorus and hsCRP (r = 0.335, P = 0.002, and r = 0.379, P < 0.001, respectively). There were a significant negative correlation between serum Klotho and serum phosphorus, FGF-23, and hsCRP (r=−0.363, P < 0.001; r=−0.220, P = 0.046; and r=−0.881, P < 0.001, respectively). Conclusion There is an association between serum levels of sclerostin, phosphorus, and FGF-23 in HD patients, and Klotho may represent an early marker of renal damage.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed2034    
    Printed218    
    Emailed0    
    PDF Downloaded191    
    Comments [Add]    
    Cited by others 1    

Recommend this journal